18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

[1]  J. Lewin,et al.  Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Mundra,et al.  Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients , 2018, European journal of cancer.

[3]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[4]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[5]  D. Schadendorf,et al.  Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. , 2017, The Lancet. Oncology.

[6]  B. Gückel,et al.  Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Michael S Hofman,et al.  How We Read Oncologic FDG PET/CT , 2016, Cancer Imaging.

[9]  C. Horak,et al.  Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. , 2016, The Lancet. Oncology.

[10]  Antoni Ribas,et al.  The “cancer immunogram” , 2016, Science.

[11]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[12]  D. Binns,et al.  Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[14]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[15]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[17]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[18]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[19]  Seong-Jang Kim,et al.  Factors Associated with Diffusely Increased Splenic F-18 FDG Uptake in Patients with Cholangiocarcinoma , 2014, Nuclear Medicine and Molecular Imaging.

[20]  H. Kim,et al.  Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma , 2013, Nuklearmedizin.

[21]  Kyoungjune Pak,et al.  Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography , 2013, Nuclear medicine communications.

[22]  O. Hoekstra,et al.  Prognostic value of the standardized uptake value for 18F-fluorodeoxyglucose in patients with stage IIIB melanoma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[24]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[25]  A. Ribas,et al.  Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab , 2010, Journal of Nuclear Medicine.

[26]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Yiyan Liu.  Clinical significance of diffusely increased splenic uptake on FDG-PET , 2009, Nuclear medicine communications.

[28]  P. Moreau,et al.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[30]  S. Zincirkeser,et al.  Standardized Uptake Values of Normal Organs on 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Imaging , 2007, The Journal of international medical research.

[31]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[32]  D. Binns,et al.  Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  R L Wahl,et al.  Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. , 1999, Radiology.

[34]  R L Wahl,et al.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.